Annexon (Nasdaq:ANNX) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

ANNX 주식 개요

임상 단계의 바이오 제약 회사인 ㈜아넥슨은 염증 관련 질환을 치료하는 의약품을 발굴하고 개발하는 기업입니다.

ANNX 기본 분석
눈송이 점수
가치 평가	1/6
미래 성장	2/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

보상

수익은 연간 68.12% 증가할 것으로 예상됩니다.

위험 분석

지난 1년 동안 주주가 크게 희석되었습니다.

수익이 1백만 달러 미만인 경우 ( $0 )

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

최근 3개월간 주가 변동성

Annexon, Inc. 경쟁사

Arbutus Biopharma

NasdaqGS:ABUS

US$568.0m

Erasca

NasdaqGS:ERAS

US$556.0m

Larimar Therapeutics

NasdaqGM:LRMR

US$502.1m

Lyell Immunopharma

NasdaqGS:LYEL

US$535.4m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Annexon
과거 주가
현재 주가	US$5.20
52주 최고치	US$8.40
52주 최저치	US$1.57
베타	1.3
11개월 변경	6.56%
3개월 변경 사항	-23.53%
1년 변경 사항	49.43%
33년 변화	-78.28%
5년 변화	n/a
IPO 이후 변화	-70.72%

최근 뉴스 및 업데이트

Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place

Jun 04

Recent updates

Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place

Jun 04

Annexon started as a buy at Jefferies on market potential of candidates, data catalysts

Sep 16

Annexon: A First Take

Aug 21

Annexon Biosciences GAAP EPS of -$0.96 misses by $0.02

Aug 08

Annexon to raise $130M in stock and warrant offering

Jul 08

We're Keeping An Eye On Annexon's (NASDAQ:ANNX) Cash Burn Rate

Apr 16

Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

Jan 01

Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

Sep 08

We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth

May 22

We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth

Feb 06

Dosing underway in Annexon's Phase 2/3 study of monoclonal antibody in Guillain-Barré Syndrome

Dec 21

Annexon Biosciences EPS misses by $0.43

Nov 16

주주 수익률

	ANNX	US Biotechs	US 마켓
7D	-7.5%	-1.3%	0.4%
1Y	49.4%	7.7%	22.9%

수익률 대 산업: ANNX 지난 1년 동안 6.7 %를 반환한 US Biotechs 산업을 초과했습니다.

수익률 대 시장: ANNX 지난 1년 동안 23.3 %를 반환한 US 시장을 초과했습니다.

가격 변동성

Is ANNX's price volatile compared to industry and market?
ANNX volatility
ANNX Average Weekly Movement	14.9%
Biotechs Industry Average Movement	10.5%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	2.9%

안정적인 주가: ANNX 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: ANNX 의 주간 변동성( 15% )은 지난 1년 동안 안정적이었지만 여전히 US 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
2011	70	Doug Love	www.annexonbio.com

임상 단계의 바이오 제약 회사인 ㈜아넥슨은 염증 관련 질환 치료를 위한 의약품을 발굴 및 개발하는 회사입니다. 주요 후보 물질로는 길랑-바레 증후군 환자 치료를 위한 임상 3상, 헌팅턴병 치료를 위한 임상 2상 완료, 근위축성 측삭 경화증 치료를 위한 임상 2상 진행 중인 연구용 전장 단클론 항체 ANX005가 있습니다. 또한 지리적 위축증 환자 치료를 위해 임상 3상을 진행 중인 항원 결합 단편(Fab) ANX007과 자가면역 적응증에 대한 임상 1상을 진행 중인 경구용 저분자 억제제 ANX1502를 개발 중입니다.

Annexon, Inc. 기본 사항 요약

Annexon 의 수익과 매출은 시가총액과 어떻게 비교하나요?
ANNX 기본 통계
시가총액	US$548.15m
수익(TTM)	-US$120.74m
수익(TTM)	n/a

0.0x

P/S 비율

-4.5x

P/E 비율

ANNX 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
ANNX 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$120.74m
수익	-US$120.74m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-1.15
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	0%

ANNX 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

ANNX 주식 개요

보상

위험 분석

Annexon, Inc. 경쟁사

NasdaqGS:ABUS

US$568.0m

NasdaqGS:ERAS

US$556.0m

NasdaqGM:LRMR

US$502.1m

NasdaqGS:LYEL

US$535.4m

가격 내역 및 성능

최근 뉴스 및 업데이트

Annexon, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

Price target increased by 13% to US$16.40

Annexon, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

Annexon, Inc. Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome

New major risk - Share price stability

Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place

Recent updates

Annexon, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

Price target increased by 13% to US$16.40

Annexon, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

Annexon, Inc. Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome

New major risk - Share price stability

Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place

Annexon, Inc. Presents New Neuro Protection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy

Annexon, Inc., Annual General Meeting, Jun 05, 2024

Annexon: Unforced Error Sullies Prospects

Price target increased by 9.0% to US$15.17

Annexon, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New minor risk - Insider selling

New major risk - Share price stability

Executive VP notifies of intention to sell stock

Annexon, Inc. has completed a Follow-on Equity Offering in the amount of $125.01642 million.

Annexon, Inc. has completed a Follow-on Equity Offering in the amount of $125.01642 million.

New major risk - Revenue and earnings growth

Here's Why We're Watching Annexon's (NASDAQ:ANNX) Cash Burn Situation

New minor risk - Market cap size

Price target increased by 10% to US$15.60

New major risk - Revenue and earnings growth

Price target increased by 9.0% to US$15.33

Annexon, Inc. Appoints Jamie Dananberg as Chief Medical Officer

Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?

Price target decreased by 18% to US$15.43

Annexon, Inc. Announces Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function

Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?

Are Investors Undervaluing Annexon, Inc. (NASDAQ:ANNX) By 25%?

Annexon, Inc. Highlights Strategic Focus to Advance Four Complement Programs Through Late-Stage Development and Progress Across Three Therapeutic Franchises

Annexon, Inc. Announces Executive Changes

We Think Annexon (NASDAQ:ANNX) Needs To Drive Business Growth Carefully

Price target decreased to US$18.71

Annexon started as a buy at Jefferies on market potential of candidates, data catalysts

Annexon: A First Take

Price target decreased to US$24.25

Annexon Biosciences GAAP EPS of -$0.96 misses by $0.02

Annexon, Inc. announced that it has received $130.475296 million in funding from a group of investors

Annexon, Inc. announced that it expects to receive $130.475296 million in funding from a group of investors

Annexon to raise $130M in stock and warrant offering

Annexon, Inc.(NasdaqGS:ANNX) dropped from Russell 2500 Index

Annexon, Inc. Reports Phase 2 Clinical Trial Results Demonstrating Upstream Classical Complement Inhibition Associated with Clinical Benefit in Huntington’S Disease

Price target decreased to US$30.80

CEO, President & Director recently bought US$147k worth of stock

We're Keeping An Eye On Annexon's (NASDAQ:ANNX) Cash Burn Rate

Price target decreased to US$30.80

Annexon Biosciences Completes Enrollment in ARCHER Phase 2 Trial of Novel C1q Inhibitor, ANX007, in Patients with Geographic Atrophy

Price target decreased to US$34.20

Annexon, Inc. Announces Resignation of Sanjay Keswani as Executive Vice President and Chief Medical Officer

Annexon, Inc. Announces Resignation of Ricky Sun as Board Member

Annexon, Inc. Reports Promising Interim Phase 2 Data Showing Improvement in Clinical Measures with ANX005

Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

Annexon Biosciences Announces Clinical and Preclinical Data Highlighting Potential of Complement-Targeting Programs at the 63rd ASH Annual Meeting & Exposition

CEO, President & Director exercised options to buy US$1.5m worth of stock.

Executive VP & Chief Scientific Officer Ted Yednock has left the company

Executive VP & Chief Scientific Officer exercised options and sold US$297k worth of stock

Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

Annexon, Inc Broadens Autoimmune Franchise with Advancement of Third Anti-C1q Product Candidate and Strategic Expansion into New Autoantibody-driven Diseases

Annexon, Inc.(NasdaqGS:ANNX) dropped from Russell 2500 Growth Index

Executive VP & CFO exercised options and sold US$52k worth of stock